시지아테크놀로지즈(SIGA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 시지아테크놀로지즈(SIGA)?

시지아테크놀로지즈(SIGA) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

Q: What is the market cap of SIGA?

The market cap of SIGA is approximately $222M, ranking 4,009 within its sector.

Q: Does SIGA pay dividends?

SIGA has a dividend yield of approximately 19.35%, with an annual dividend of $0.60.

Q: What is the P/E ratio of SIGA?

SIGA has a P/E ratio of approximately 11.0x, which can be used to assess its valuation relative to the Healthcare sector average.

Q: What is the 52-week high and low for SIGA?

SIGA has recorded a 52-week high of $8.51 and a low of $3.03.

SIGA

SIGA Technologies Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$3.10

-0.01 ▼ -0.32%

🌙 7월 28일 8:52 AM ET (한국 7/28 21:52)

$3.10

+0.00 +0.00%

시지아테크놀로지즈(SIGA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$222M

스몰캡

P/E

11.0

저평가 구간

배당수익률

19.35%

52주 위치

저점 +2% · 고점 -64%

애널리스트

C+

Fundamental health

vs. Drug Manufacturers - Specialty & Generic

수익성

Top 2%

성장

Top 73%

밸류에이션

Top 72%

재무 안정

Top 58%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 5년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 11원. Over the past 5년, it usually traded around 9원. Roughly in line with its own history.

Pricy doesn't mean bad — it means expectations are already baked in.

Index ⓘ	RUT	P/E ⓘ	11.01	EPS (ttm) ⓘ	0.28	Insider Own ⓘ	42.83%	Shs Outstand ⓘ	71.7M	Perf Week ⓘ	-10.92%
Market Cap ⓘ	0.22B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	41.0M	Perf Month ⓘ	-21.52%
Enterprise Value ⓘ	0.08B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	48.3%	Short Float ⓘ	9.59%	Perf Quarter ⓘ	-32.17%
Income ⓘ	0.02B	P/S ⓘ	2.37	EPS this Y ⓘ	-	Inst Trans ⓘ	-2.92%	Short Ratio ⓘ	7.14	Perf Half Y ⓘ	-47.22%
Sales ⓘ	0.09B	P/B ⓘ	1.47	EPS next 5Y ⓘ	-	ROA ⓘ	8.68%	Short Interest ⓘ	3.93M	Perf YTD ⓘ	-42.65%
Book/sh ⓘ	2.11	P/C ⓘ	1.53	EPS past 3/5Y ⓘ	-10.75% -14.51%	ROE ⓘ	11%	52W High ⓘ	-63.57% ($8.51)	Perf Year ⓘ	-50.92%
Cash/sh ⓘ	2.03	P/FCF ⓘ	8.11	Sales past 3/5Y ⓘ	-5.13% -5.42%	ROIC ⓘ	13.34%	52W Low ⓘ	2.31% ($3.03)	Perf 3Y ⓘ	-18.38%
Dividend Est. ⓘ	$0.6 (19.35%)	EV/EBITDA ⓘ	3.65	EPS Y/Y TTM ⓘ	-58.28%	Gross Margin ⓘ	65.36%	Volatility(W/M) ⓘ	5.67% 5.54%	Perf 5Y ⓘ	-21.55%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.83	Sales Y/Y TTM ⓘ	-22.07%	Oper. Margin ⓘ	22.01%	ATR (14) ⓘ	0.17	Perf 10Y ⓘ	108.07%
Dividend Ex-Date ⓘ	2026/4/7	Quick Ratio ⓘ	2.38	EPS Q/Q ⓘ	-745.61%	Profit Margin ⓘ	21.58%	RSI (14) ⓘ	27.79	Recom ⓘ	-
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	3.25	Sales Q/Q ⓘ	-11.34%	SMA20 ⓘ	-11.78% ($3.51)	Beta ⓘ	0.99	Target Price ⓘ	$11.48
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	2026/5/7	SMA50 ⓘ	-23.13% ($4.03)	Rel Volume ⓘ	7.2	Prev Close ⓘ	$3.11
Employees ⓘ	49	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-40.34% ($5.2)	Avg Volume(3M) ⓘ	0.55M	Price ⓘ	$3.1
IPO ⓘ	1997/9/9	Option/Short ⓘ	Yes/Yes			Trades ⓘ	9778	Volume ⓘ	3,966,243	Change ⓘ	-0.32%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $6M (YoY -11%) · 순이익 $-3M (YoY -746%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 SIGA Technologies Inc (SIGA) Investment Analysis

What kind of company is SIGA Technologies Inc?

시지아테크놀로지즈(SIGA) 배당주

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

SIGA Technologies is a U.S. biodefense company developing antiviral treatments targeting high-risk pathogens such as smallpox and mpox (monkeypox). Centered on its core product TPOXX—an antiviral therapy available in both oral and intravenous formulations—the company operates a public health security-focused business model, generating revenue through U.S. government stockpiling contracts and procurement agreements with foreign governments.

Learn more about SIGA Technologies Inc →

Market Cap

$0.2B

Approx. KRW 0.3 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4009

Employees49people

IPO1997/09/09

Current Price$3.10 ≈ 4,247원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후

🎯 Ex-div 2026년 4월 7일 (화)

🔔 Earnings release 2026년 3월 10일 (화) · 장 마감 후

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

22.0%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median -37.1% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

21.6%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median -38.2% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

65.4%

✓ 우수

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Top 11%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

11.0%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -98.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

8.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

13.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

3.25

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.38

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$11.48

현재가 대비 +270.3%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-10.8%

평균

My positionMid-range

Low range Average High range

배당주 초소형주 Median -7.5% · Bottom 46%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-14.5%

부진

My positionBottom 25%

Low range Average High range

배당주 초소형주 Median -0.7% · Bottom 22%

Past 5-Year Revenue

How much revenue grew over the past 5 years

-5.4%

부진

My positionBottom 25%

Low range Average High range

배당주 초소형주 Median 5.5% · Bottom 16%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-11.3%

평균

My positionMid-range

Low range Average High range

배당주 초소형주 Median -1.4% · Bottom 26%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -90%p below the market

SIGA -21.6% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-89.9%p

Significantly behind the market

vs Health Care (XLV)

-46.0%p

Significantly behind the sector average

1-year basis

vs S&P 500

-66.9%p

Significantly behind the market

vs Health Care (XLV)

-70.6%p

Significantly behind the sector average

Rank among peers

5-year return Top among peers Based on 28 peers

1-year return Lower-Mid (lower 42%) Based on 36 peers

Current position within 52-week range

Low (-2.3%p) High (-63.6%p)

Current price is 2.3% above the 52-week low and 63.6% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-55.2%

Annualized volatility

49.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

Current price $3.10 fell below the lower band ($3.11). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.245 < Signal -0.222 in negative zone + Hist negative (-0.023). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

RSI 28.0 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 11.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Cash Flow, In line with peers on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

11.01x

✓ Very cheap

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 20.36x · Top 1% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.47x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 0.78x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

2.37x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

3.65x

✓ Very cheap

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 10.57x · Top 1% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

8.11x

✓ Very cheap

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Top 21% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$11.48 vs. current price +270.3%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership backdrop is unfavorable

Institutional net selling -2.9% · Short interest moderate 9.6% · Short interest up +1.3pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-2.9%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 48.3%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 42.8%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 8.9%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

9.6%

Moderate

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +1.3%p increase

Short interest days to cover

7.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 71.7M주

Float (tradable shares) 41.0M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding SIGA

ETFs with the highest weightings · 10 total shown

ABLS

Abacus FCF Small Cap Leaders ETF

1.13%

DEEP

Acquirers Small and Micro Deep Value ETF

0.97%

$27M

MYLD

Cambria Micro and SmallCap Shareholder Yield ETF

0.65%

$34M

QQQS

Invesco NASDAQ Future Gen 200 ETF

0.50%

$21M

FDM

First Trust Dow Jones Select Microcap Index Fund

0.31%

$260M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

고배당주 — 연 19.35% 배당

Dividend Yield

19.35%

Industry average 1.23%

Dividend Per Share

$0.60

Annualized

Payout Ratio

Share of net income paid as dividends

5-Year Growth

Annualized dividend growth

📅 지급월 4월

📊 총 이력 2022~2026 (5건)

연도별 배당 총액 추이

주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.

$0.45

2022

$0.45 +0.0%

2023

$0.60 +33.3%

2024

$0.60 +0.0%

2025

$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소

최근 배당 이력 총 5건

아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.

배당락일

주당 금액

지급일

당시 수익률

2026-04-07

$0.600

—

26.49%

2025-04-29

$0.600

—

10.42%

2024-03-25

$0.600

—

12.57%

2023-05-15

$0.450

—

15.52%

2022-05-16

$0.450

—

6.11%

* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.

💰 내가 100만원 투자한다면

연간 배당금 (세후) 16.5만원

5년 누적 (세후) 82.3만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
SIGA This Stock	$222.3M	11.0 ▲	1.5 ▲	11% ▲	19.35% ▲	-0.3%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 시지아테크놀로지즈(SIGA)?

시지아테크놀로지즈(SIGA) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of SIGA?

The market cap of SIGA is approximately $222M, ranking 4,009 within its sector.

Does SIGA pay dividends?

SIGA has a dividend yield of approximately 19.35%, with an annual dividend of $0.60.

What is the P/E ratio of SIGA?

SIGA has a P/E ratio of approximately 11.0x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for SIGA?

SIGA has recorded a 52-week high of $8.51 and a low of $3.03.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.